ZLZenghua Lin

Zenghua Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zenghua Lin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shengmai Yin Attenuates Hypobaric Hypoxia-Induced Erythrocyte Echinocytosis by Restoring Redox Homeostasis and Normalizing Band 3–Syk/SHP2 Interactions

    by Jie Ding, Jiali Hua, Lingyi Meng, Chenyan Lu, Jiawei Liu, Zenghua Lin, Guohua Wang, Qianqian Luo

    Acute exposure to high-altitude hypobaric hypoxia (HH) disrupts redox homeostasis and impairs erythrocyte morphology and oxygen transport. Shengmai Yin (SMY) is a botanical formulation with reported antioxidant activity, but its effects on HH-induced erythrocyte injury remain unclear. Male C57BL/6J mice received SMY in drinking water for 3 days before 24 h of simulated HH equivalent to 6000 m. Complementary in vivo and in vitro experiments assessed redox indices, lipid peroxidation, hemoglobin redox status, erythrocyte morphology, arterial oxygenation, and Band 3-associated protein interactions. HH increased serum DHE-derived fluorescence, nitric oxide, and malondialdehyde, reduced antioxidant capacity, induced echinocytosis, decreased oxyhemoglobin, and increased methemoglobin. Among the tested redox challenges, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) most closely reproduced the combined morphological and hemoglobin abnormalities. SMY scavenged DPPH, hydroxyl-radical, and superoxide-related signals in cell-free assays; reduced PTIO- and hypoxia-induced erythrocyte damage; and reversed established echinocytosis within 30 min in vitro. In mice, SMY reduced echinocytosis and improved arterial oxygenation without detectable short-term hepatic, renal, or histological toxicity. SMY also normalized HH- and PTIO-induced changes in Band 3 interactions with Syk and SHP2. These findings support SMY as a redox-modulating intervention that preserves erythrocyte structure and function during acute HH.

  • Open Access

    Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma

    by Yuejiao Huang, Jiawen Jiang, Jinfeng Lu, Chunfeng Sun, Juan Qian, Xuefen You, Zenghua Lin

    Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient’s documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton’s tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient’s CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.